RealiseD Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases
- Coordinator
- Sigmund Freud Privatuniversitat Wien GmbH, Austria
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €8.5m
- Total cost
- €17.2m
- Partners
- 53 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101165912
What the project is doing
In the project's own words, from its summary on CORDIS.
RealiseD implements a collaborative and compRehensive mEthodological and operational Approach to cLinical trIalS in rarE Diseases enabling timely drug development and approval centred on patients’ needs with high level of evidence reachable in a limited environment. The core of RealiseD operational approaches includes the systematic procedures for patients’ referral, the certification of clinical sites and filling the gaps for successful development of rare and ultra rare diseases[(U)RD]’ clinical trials using 4 (U)RD diseases from 4 European Research Networks (ERNs).
RealiseD methodological teams will optimise innovative statistical and quantitative approaches for design and analysis of (U)RD-CTs developed in the past 10 years and refined in the last years to facilitate the regulatory pathway for innovative drug development. RealiseD is implemented in a public private partnership consortium including regulators and HTA bodies representatives to co-create operational and methodological approaches in an iterative procedure using a multistakeholders’ agreement process.
RealiseD will increase the incentives and motivation for the pharmaceutical industry by reducing many uncertainties on the path of drug development in (U)RD that will follow widely accepted rules. To achieve these innovative approaches, RealiseD will capitalise on an international multistakeholders effort as the problem in (U)RD drug development cannot be solved in a restricted geographical area. With the development and deployment of playbooks arising from the co-created developments, RealiseD will ascertain visibility and readiness of the innovations.
The overall ambition of RealiseD is to change the paradigm of CT design for U(RD) by enlarging the spectrum of methodological and operational approaches and to establish a sustainable, innovative, and optimised CT paradigm for U(RD) medicinal product development programs, while maximizing the acceptance by all stakeholders.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Sigmund Freud Privatuniversitat Wien GmbH | Wien | Austria | Coordinator |
| Genzyme Argentinia S.A. | Martinez | AR | Associatedpartner |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Paris-Lodron-Universitat Salzburg | Salzburg | Austria | Participant |
| International Drug Development Institute SA | Ottignies-Louvain-La-Neuve | Belgium | Participant |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| Sanofi-Aventis Belgium SA | Diegem | Belgium | Associatedpartner |
| Ucb Biopharma | Bruxelles / Brussel | Belgium | Participant |
| Universiteit Gent | Gent | Belgium | Participant |
| Universiteit Hasselt | Hasselt | Belgium | Participant |
| Bayer Consumer Care AG | Basel | Switzerland | Associatedpartner |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Boehringer Ingelheim Internationalgmbh | Ingelheim | Germany | Participant |
| Boehringer Ingelheim Pharma GmbH &co Kg | Ingelheim | Germany | Associatedpartner |
| Otto-Von-Guericke-Universitaet Magdeburg | Magdeburg | Germany | Participant |
| Ruhr-Universitaet Bochum | Bochum | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Associatedpartner |
| Stiftung Fur Qualitat Und Wirtschaftlichkeit Im Gesundheitswesen | Berlin | Germany | Participant |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | Goettingen | Germany | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Participant |
| Fundacio Privada per a La Recerca I La Docencia Sant Joan De Deu | Esplugues De Llobregat | Spain | Third party |
| Hospital Sant Joan De Deu | Esplugues De Llobregat | Spain | Participant |
| Sanofi Aventis SA | Barcelona | Spain | Associatedpartner |
| Teamit Research S.l. | Barcelona | Spain | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Eurordis - Rare Diseases Europe | Paris | France | Participant |
| Hopitaux Universitaires De Strasbourg | Strasbourg Cedex | France | Participant |
| Institut De Recherches Internationales Servier | Gif-Sur-Yvette | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Ipsen Innovation SAS | Paris | France | Participant |
| Sanofi Winthrop Industrie | Gentilly | France | Associatedpartner |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Participant |
| Azienda Sanitaria Universitaria Friuli Centrale | Udine | Italy | Participant |
| Istituto Ortopedico Rizzoli | Bologna | Italy | Participant |
| Sanofi Srl | Milano | Italy | Associatedpartner |
| Universita Humanitas | Pieve Emanuele | Italy | Participant |
| Conect4children Stichting | Utrecht | Netherlands | Participant |
| Critical Path Institute Stichting | Amsterdam | Netherlands | Participant |
| Eatris Eric | Amsterdam | Netherlands | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| The European Medicines Agency | Amsterdam | Netherlands | Participant |
| Universitetet I Oslo | Oslo | Norway | Third party |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| Bayer Public Limited Company | Newbury | United Kingdom | Associatedpartner |
| Alexion Pharmaceuticals Inc | Boston | United States | Associatedpartner |
| Janssen Research & Development, LLC | Raritan | United States | Associatedpartner |
| Sanofi Genzyme | Cambridge | United States | Associatedpartner |
| Sanofi US Services Inc. | Cambridge, Massachusetts | United States | Associatedpartner |
| Servier BIO-INNOVATION LLC | Boston | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI